Discovery - University of Dundee - Online Publications

Library & Learning Centre

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer

Standard

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. / Smith, G. (Lead / Corresponding author); Ng, M. T. H.; Shepherd, L.; Herrington, C.S.; Gourley, C.; Ferguson, Michelle; Wolf, C.R.

In: British Journal of Cancer, Vol. 107, No. 8, 09.10.2012, p. 1327-1336.

Research output: Contribution to journalArticle

Harvard

Smith, G, Ng, MTH, Shepherd, L, Herrington, CS, Gourley, C, Ferguson, M & Wolf, CR 2012, 'Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer' British Journal of Cancer, vol 107, no. 8, pp. 1327-1336., 10.1038/bjc.2012.410

APA

Smith, G., Ng, M. T. H., Shepherd, L., Herrington, C. S., Gourley, C., Ferguson, M., & Wolf, C. R. (2012). Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. British Journal of Cancer, 107(8), 1327-1336. 10.1038/bjc.2012.410

Vancouver

Smith G, Ng MTH, Shepherd L, Herrington CS, Gourley C, Ferguson M et al. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. British Journal of Cancer. 2012 Oct 9;107(8):1327-1336. Available from: 10.1038/bjc.2012.410

Author

Smith, G. (Lead / Corresponding author); Ng, M. T. H.; Shepherd, L.; Herrington, C.S.; Gourley, C.; Ferguson, Michelle; Wolf, C.R. / Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.

In: British Journal of Cancer, Vol. 107, No. 8, 09.10.2012, p. 1327-1336.

Research output: Contribution to journalArticle

Bibtex - Download

@article{a63f52ce26884736ac2e7f9eaf61d872,
title = "Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer",
keywords = "SEROUS CARCINOMA, DISEASES, GENE-EXPRESSION, ovarian cancer, platinum drugs, FIBROBLAST-GROWTH-FACTOR, SUBTYPES, PSORIASIS, fibroblast growth factors, chemotherapy, GLUTATHIONE-S-TRANSFERASE, BEVACIZUMAB, CISPLATIN, survival, MUTATIONS",
author = "G. Smith and Ng, {M. T. H.} and L. Shepherd and C.S. Herrington and C. Gourley and Michelle Ferguson and C.R. Wolf",
year = "2012",
doi = "10.1038/bjc.2012.410",
volume = "107",
number = "8",
pages = "1327--1336",
journal = "British Journal of Cancer",
issn = "0007-0920",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer

A1 - Smith,G.

A1 - Ng,M. T. H.

A1 - Shepherd,L.

A1 - Herrington,C.S.

A1 - Gourley,C.

A1 - Ferguson,Michelle

A1 - Wolf,C.R.

AU - Smith,G.

AU - Ng,M. T. H.

AU - Shepherd,L.

AU - Herrington,C.S.

AU - Gourley,C.

AU - Ferguson,Michelle

AU - Wolf,C.R.

PY - 2012/10/9

Y1 - 2012/10/9

N2 - <p>BACKGROUND: Ovarian cancer is frequently advanced at presentation when treatment is rarely curative. Response to first-line platinum-based chemotherapy significantly influences survival, but clinical response is unpredictable and is frequently limited by the development of drug-resistant disease.</p><p>METHODS: We used qRT-PCR analysis to assess intertumour differences in the expression of fibroblast growth factor 1 (FGF1) and additional candidate genes in human ovarian tumours (n = 187), and correlated individuality in gene expression with tumour histology, chemotherapy response and survival. We used MTT assays to assess platinum chemosensitivity in drug-sensitive and drug-resistant ovarian cell lines.</p><p>RESULTS: Marked intertumour differences in gene expression were observed, with each tumour having a unique gene expression profile. Nine genes, including FGF1 (P = 1.7 x 10(-5)) and FGFR2 (P = 0.003), were differentially expressed in serous and nonserous tumours. MDM2 (P = 0.032) and ERBB2 (P = 0.064) expression was increased in platinum-sensitive patients, and FGF1 (adjusted log-rank test P = 0.006), FGFR2 (P = 0.04) and PDRFRB expression (P = 0.037) significantly inversely influenced progression-free survival. Stable FGF1 gene knockdown in platinum-resistant A2780DPP cells re-sensitised cells to both cisplatin and carboplatin.</p><p>CONCLUSION: We show for the first time that FGF1 is differentially expressed in high-grade serous ovarian tumours, and that individuality in FGF1 expression significantly influences progression-free survival and response to platinum-based chemotherapy. British Journal of Cancer (2012) 107, 1327-1336. doi:10.1038/bjc.2012.410 www.bjcancer.com Published online 18 September 2012 (C) 2012 Cancer Research UK</p>

AB - <p>BACKGROUND: Ovarian cancer is frequently advanced at presentation when treatment is rarely curative. Response to first-line platinum-based chemotherapy significantly influences survival, but clinical response is unpredictable and is frequently limited by the development of drug-resistant disease.</p><p>METHODS: We used qRT-PCR analysis to assess intertumour differences in the expression of fibroblast growth factor 1 (FGF1) and additional candidate genes in human ovarian tumours (n = 187), and correlated individuality in gene expression with tumour histology, chemotherapy response and survival. We used MTT assays to assess platinum chemosensitivity in drug-sensitive and drug-resistant ovarian cell lines.</p><p>RESULTS: Marked intertumour differences in gene expression were observed, with each tumour having a unique gene expression profile. Nine genes, including FGF1 (P = 1.7 x 10(-5)) and FGFR2 (P = 0.003), were differentially expressed in serous and nonserous tumours. MDM2 (P = 0.032) and ERBB2 (P = 0.064) expression was increased in platinum-sensitive patients, and FGF1 (adjusted log-rank test P = 0.006), FGFR2 (P = 0.04) and PDRFRB expression (P = 0.037) significantly inversely influenced progression-free survival. Stable FGF1 gene knockdown in platinum-resistant A2780DPP cells re-sensitised cells to both cisplatin and carboplatin.</p><p>CONCLUSION: We show for the first time that FGF1 is differentially expressed in high-grade serous ovarian tumours, and that individuality in FGF1 expression significantly influences progression-free survival and response to platinum-based chemotherapy. British Journal of Cancer (2012) 107, 1327-1336. doi:10.1038/bjc.2012.410 www.bjcancer.com Published online 18 September 2012 (C) 2012 Cancer Research UK</p>

KW - SEROUS CARCINOMA

KW - DISEASES

KW - GENE-EXPRESSION

KW - ovarian cancer

KW - platinum drugs

KW - FIBROBLAST-GROWTH-FACTOR

KW - SUBTYPES

KW - PSORIASIS

KW - fibroblast growth factors

KW - chemotherapy

KW - GLUTATHIONE-S-TRANSFERASE

KW - BEVACIZUMAB

KW - CISPLATIN

KW - survival

KW - MUTATIONS

UR - http://www.scopus.com/inward/record.url?scp=84866144189&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.410

DO - 10.1038/bjc.2012.410

M1 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

VL - 107

SP - 1327

EP - 1336

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy